Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pravachol OTC Deal Reached Between Bayer, Bristol

This article was originally published in The Tan Sheet

Executive Summary

Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S
Advertisement

Related Content

Bayer Pravachol switch program still alive
Bayer Pravachol switch program still alive
Bayer Poised To “Seize Opportunities” After Rapid Integration Of Roche OTCs
Return of the Switch? A Fallow 2005 Sowed the Seeds for Future Switches
Bayer Stake In OTC Pravachol Could Influence Bristol OTC Unit Divestiture
Statin Rx-To-Oh-We’ll See: Bristol’s Dolan Guarded On Pravachol Switch
OTC Statins: What We Have Is A Failure To Communicate
Merck Foresees Addition By Subtraction For Rx Statins If Mevacor Goes OTC
Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement
Non-Rx Zocor Will Be Available In UK Without Cholesterol Screen Requirement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel